OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Stadler on the Utility of Germline Profiling for Targeted Interventions in Advanced Cancer

June 5th 2020

Zsofia K. Stadler, MD, discusses a study evaluating the clinical utility of germline mutation profiling of targeted therapeutic interventions in a pan-cancer patient population.

Dr. Husain on Common Misconceptions in Lung Cancer

June 5th 2020

Hatim Husain, MD, discusses common misconceptions that still exist with regard to lung cancer.

Dr. Hoffman on the Current Polycythemia Vera Treatment Paradigm

June 5th 2020

Ronald Hoffman, MD, discusses the current polycythemia vera treatment paradigm.

Dr. Rodriguez-Abreu on Updated Results From the KEYNOTE-189 Trial in NSCLC

June 5th 2020

Delvys Rodriguez-Abreu, MD, discusses findings from the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.

Dr. Mascarenhas on the Impact of Ruxolitinib on the Myelofibrosis Treatment Paradigm

June 5th 2020

John O. Mascarenhas, MD, discusses the impact of ruxolitinib in the myelofibrosis treatment paradigm.

Dr. Gwin on the Mechanism of Action of Alpha-TEA in HER2-Positive Metastatic Breast Cancer

June 5th 2020

William R. Gwin III, MD, discusses the mechanism of action of alpha-tocopheryloxyacetic acid in HER2-positive metastatic breast cancer.

Dr. Jacobson on the Safety Profile of Axi-Cel in Relapsed/Refractory Indolent Lymphoma

June 5th 2020

Caron Jacobson, MD, discusses the safety profile of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Nelson on the Future Utility of ctDNA in CRC

June 5th 2020

Douglas A. Nelson, MD, discusses the future utility of circulating tumor DNA in colorectal cancer.

Dr. Sharman on the Results of the GENUINE Trial in CLL

June 5th 2020

Jeff P. Sharman, MD, discusses the results of the phase 3 GENUINE trial in chronic lymphocytic leukemia.

Dr. Dimopoulos on the Evolution of Selinexor in Multiple Myeloma

June 5th 2020

Meletios A. Dimopoulos, MD, discusses the evolution of selinexor in multiple myeloma.

Dr. Simeone on the Importance of Germline Testing in Pancreatic Cancer

June 5th 2020

Diane M. Simeone, MD, discusses the importance of germline testing in pancreatic cancer.

Dr. Kelly on the Rationale for Combining Radium-223 and Niraparib in mCRPC

June 5th 2020

William Kevin Kelly, DO, discusses the rationale for a phase 1b dose-finding study evaluating the combination radium-223 dichloride and niraparib in patients with metastatic castration-resistant prostate cancer.

Dr. Lee on Combining TKIs With Immunotherapy in mRCC

June 4th 2020

Chung-Han Lee, MD, PhD, discusses the potential for combining TKIs with immunotherapy in patients with metastatic renal cell carcinoma who have progressed on prior checkpoint inhibitors.

Dr. Richardson on the Mechanism of Action of CC-92480 in Multiple Myeloma

June 4th 2020

Paul G. Richardson, MD, discusses the mechanism of action of CC-92480 in patients with multiple myeloma.

Dr. Klein on Predicting Tumor Aggressiveness With Oncotype DX Test in Prostate Cancer

June 4th 2020

Eric A. Klein, MD, discusses the Oncotype DX test and how it is utilized to predict tumor aggressiveness in patients with prostate cancer.

Dr. Chi on the Prostate Cancer Biomarker Enrichment and Treatment Selection Study

June 4th 2020

Kim Chi, MD, discusses prostate cancer biomarker enrichment and treatment selection study.

Dr. Wolf on Updated Findings With Capmatinib in METex14-Mutant NSCLC

June 4th 2020

Jüergen Wolf, MD, discusses data the phase 2 GEOMETRY mono-1 trial with capmatinib (Tabrecta) in patients with METex14-mutated or high MET amplified advanced non–small cell lung cancer.

Dr. Armaghany on the Utility of ctDNA in CRC

June 4th 2020

Tannaz Armaghany, MD, discusses the utility of circulating tumor DNA in colorectal cancer.

Dr. Favret on Extending Survival and Improving Outcomes in Breast Cancer

June 4th 2020

Anne Favret, MD, discusses the importance of clinical trials in the breast cancer space.

Dr. Lenz on the Updated Findings From the CheckMate-142 Trial in mCRC

June 4th 2020

Heinz-Josef Lenz, MD, FACP, discusses the updated findings from the phase 2 CheckMate-142 trial in previously untreated patients with microsatellite instability–high (MSI-H)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC).